Cluster headache in the United States of America: demographics, clinical characteristics, triggers, suicidality, and personal burden.
Todd D Rozen, Royce S Fishman
https://pubmed.ncbi.nlm.nih.gov/22077141/Actively Recruiting
Led by Radboud University Medical Center · Updated on 2025-04-15
65
Participants Needed
2
Research Sites
N/A
Total Duration
Researchers are evaluating the efficacy and safety of low-dose LSD 25 micrograms every 3 days for 3 weeks compared to placebo in treating chronic cluster headache cCH. This phase 2, randomized, double-blind, placebo-controlled trial includes a 4-week baseline observation period before treatment and a 5-week post-treatment observation period. The study aims to assess whether LSD can reduce headache attack frequency and improve health-related quality of life while exploring safety, exposure-response relationships, and cost-effectiveness. Participants receive either LSD tartrate or a placebo vial every 3 days for 3 weeks, totaling seven doses. The study is conducted in an ambulatory setting, and the blinded treatment phase is followed by a post-treatment observation period lasting 5 weeks to assess sustained effects. The placebo is designed to look identical to the LSD vial to maintain study blinding. During the study, participants track their headache attack frequency and severity, medication use, and quality of life. Researchers collect data on weekly attack frequency, attack duration, severity, use of abortive medications, and global impression of change. Safety assessments include screening for psychosis risk, drug use, and pregnancy status. The total participation includes baseline, treatment, and follow-up periods to monitor both short-term and sustained treatment effects.
CONDITIONS
LSD to Improve Cluster Headache Impact Trial
J
Julia Jansen, MD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Radboud University Medical Center
Lead Sponsor
ZonMw: The Netherlands Organisation for Health Research and Development
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 3 weeks
Participants receive a dose of LSD or placebo every 3 days for 3 weeks to assess the efficacy of LSD as a prophylactic treatment for chronic cluster headache.
7 dosing visits every 3 days
Duration - 5 weeks
Participants are monitored for sustained response and safety for 5 weeks after treatment ends.
Visits at weeks 4 and 8 post-randomization
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Todd D Rozen, Royce S Fishman
https://pubmed.ncbi.nlm.nih.gov/22077141/Ilse F de Coo, Willemijn C Naber, Leopoldine A Wilbrink...
https://pubmed.ncbi.nlm.nih.gov/30290701/R Andrew Sewell, John H Halpern, Harrison G Pope
https://pubmed.ncbi.nlm.nih.gov/16801660/Brian E McGeeney
https://pubmed.ncbi.nlm.nih.gov/23278122/Emmanuelle A D Schindler, Christopher H Gottschalk, Marsha J Weil...
https://pubmed.ncbi.nlm.nih.gov/26595349/Stewart J Tepper, Mark J Stillman
https://pubmed.ncbi.nlm.nih.gov/23808603/Martin Andersson, Mari Persson, Anette Kjellgren
https://pubmed.ncbi.nlm.nih.gov/28870224/Jan Hoffmann, Arne May
https://pubmed.ncbi.nlm.nih.gov/29174963/Radboud University Medical Center
Lead Sponsor
ZonMw: The Netherlands Organisation for Health Research and Development
Collaborating Sponsor